Jefferies Group LLC Durect Corp Transaction History

Jefferies Group LLC

$10.2 Billion
Q3 2022

A detailed history of Jefferies Group LLC transactions in Durect Corp stock. As of the latest transaction made, Jefferies Group LLC holds 275,653 shares of DRRX stock, worth $355,592. This represents 0.0% of its overall portfolio holdings.

Number of Shares

275,653

Previous 275,653 -0.0%

Holding current value

$355,592

Previous $132,000 6.06%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Sep 21, 2023	SELL	$0.38 - $0.64 $285,000 - $480,000	-750,000 Reduced 73.12%	275,653 $132,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $0.64 $285,000 - $480,000	-750,000 Reduced 73.12%	275,653 $132,000
Q1 2022 Sep 21, 2023	BUY	$0.55 - $0.98 $96,250 - $171,500	175,000 Added 20.57%	1,025,653 $687,000
Q1 2022 May 16, 2022	BUY	$0.55 - $0.98 $59,620 - $106,232	108,400 Added 11.82%	1,025,653 $687,000
Q4 2021 Feb 14, 2022	BUY	$0.9 - $1.31 $59,940 - $87,246	66,600 Added 7.83%	917,253 $869,000

Q2 2021 Sep 21, 2023	SELL	$1.6 - $2.02 $280,000 - $353,500	-175,000 Reduced 17.06%	850,653 $1.39 Million
Q2 2021 Aug 16, 2021	SELL	$1.6 - $2.02 $280,000 - $353,500	-175,000 Reduced 17.06%	850,653 $1.39 Million
Q4 2020 Sep 21, 2023	BUY	$1.65 - $2.43 $1.24 Million - $1.82 Million	750,000 Added 272.08%	1,025,653 $2.12 Million
Q2 2020 Aug 14, 2020	BUY	$1.33 - $2.76 $100,990 - $209,575	75,933 Added 8.0%	1,025,653 $2.38 Million
Q1 2020 May 15, 2020	BUY	$0.97 - $2.85 $921,228 - $2.71 Million	949,720 New	949,720 $1.47 Million
Q4 2018 Feb 14, 2019	SELL	$0.48 - $1.1 $9,216 - $21,120	-19,200 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$1.06 - $1.69 $20,352 - $32,448	19,200 New	19,200 $21,000

Others Institutions Holding DRRX

# of Institutions

Shares Held

559K

Call Options Held

Put Options Held

View Full List

About DURECT CORP

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $294M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

More about DRRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.

Account

Jefferies Group LLC Durect Corp Transaction History